Abstract 1344
Background
Individual chemotherapy based on the determination of molecular biomarkers of chemosensitivity is a new way to treat patients with NSCLC. Promising markers for chemosensitivity are monoresistance genes such as BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBB3, TYMS, and ABCC5.
Methods
We enrolled and analyzed 62 patients with stage III NSCLC. All the patients have received 2 courses of neoadjuvant chemotherapy vinorelbine/carboplatin and surgery. Then patients were randomly assigned (1:1 ratio) to either the personalized adjuvant chemotherapy arm (main group) or the adjuvant chemotherapy vinorelbine/carboplatin arm (control group). In the main group, carboplatin-containing doublets were assigned based on monoresistance gene expression levels ABCC5, RRM1, ERCC1, BRCA1, TOP1, TOP2α, TUBB3 and TYMS. RNA was extracted from tumor after neoadjuvant chemotherapy using “RNeasy Plus Mini Kit” (QIAGEN, Germany). The analysis of monoresistance genes expression was done by qRT-PCR method. A χ2 test was used to analyze gene expression in relation to clinicopathological parameters. The survival rates were calculated by the Kaplan-Meier method.
Results
The follow-up period was 4 - 76 months. In the main group, the disease progression was observed in 6 patients (19.4%), in the control group - 15 patients (48.4%). Three-year disease-free survival in the main group was 80.7% (median DFS not achieved), in the control group - 51.6%, median DFS - 34 months (HR: 2.56, 95% CI: 1.09 - 6,03); differences are statistically significant: Log-Rank test χ2=4.196, p = 0.041. There was no difference in three-year overall survival (main group: 87.1%, control group: 67.7%, HR: 2.27, 95% CI: 0.79 - 6,47).
Conclusions
Personalized postoperative chemotherapy based on the determination of monoresistance gene expression after neoadjuvant chemotherapy allows significant increase of patients 3-year disease-free survival by 29.1%.
Clinical trial identification
Legal entity responsible for the study
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract